Short description:
Biologics
Drug notes:
SRK-181 Clin1 immuno-oncology; 2 undisclosed programs RD/Clin0 anemia, fibrosis
Long description:
Scholar Rock is discovering new medicines that target inactive forms of growth factors to treat disease. Growth factors in their active form are common therapeutic targets, since they are extracellular and drivers of disease. However, many mature, active forms of different growth factors are structurally similar, limiting drug specificity. Scholar Rock is targeting the inactive precursor, or latent, forms of growth factors to regulate their activity in the tissue microenvironment. To identify therapeutics, Scholar Rock is using their proprietary platform to develop antibody drugs that recognise the prodomain of precursor growth factors. Scholar Rock’s lead candidate, Apitegromab, is in Phase 3 clinical trials for patients with Spinal Muscular Atrophy.
Jobs:
VP, Head of Medical Affairs Cambridge, MAHybrid|5 days ago
Scientist/Sr. Scientist, Device Engineering- Drug ... Cambridge, MAHybrid|15 days ago
Associate Director of Payroll Cambridge, MAHybrid|21 days ago
Talent Acquisition/Learning & Development Coordina... Cambridge, MAHybrid|41 days ago
Senior Manager, Supply Chain Cambridge, MAHybrid|54 days ago
Medical Director, Safety & Pharmacovigilance RemoteRemote|62 days ago
TechOps Intern - Analytical Development Cambridge, MA/ On-site|74 days ago
In-House Clinical Research Associate Remote/ Remote|90 days ago
Director of Clinical Pharmacology Remote/ Remote|97 days ago
Sr. Associate Scientist Cambridge, MA/ On-site|97 days ago
Program Leader Cambridge, MA/ Hybrid|100+ days ago